Glycoprotein Structure Analysis
Glycoproteins are widely used in biomedicine, but their complex structure and heterogeneity can be obstacles in research. We have developed a structure analysis platform with multiple world-leading technologies to help customers comprehensively progress in glycoprotein research. CD BioGlyco has the confidence to be your essential research assistant in the field of glycobiology.
Overview of Glycoprotein Structure Analysis
Glycosylation is one of the most common protein post-translational modifications. It usually determines the folding and transport of proteins, and regulates almost all extracellular activities, including cell-to-cell communication and cell-matrix interactions. It has been shown that specific glycosylation changes are the key to disease progression and can have diagnostic value for multiple disease types, such as cancer and inflammation. Therefore, glycoproteins can be used as effective biomarkers for disease detection and targets for drug and vaccine development. Although glycoproteins are important, the complex structure of carbohydrates and their derivatives in biological samples makes the global analysis of glycoproteins extremely challenging.
In recent years, mass spectrometry (MS) has become a powerful tool for glycoprotein analysis. The microarray platform has also become an indispensable tool for characterizing glycan structures and studying glycosylation-related biological interactions. Although the emergence of mass spectrometry-based proteomics research provides huge opportunities for the analysis of glycoproteins, the low abundance of many glycoproteins and the heterogeneity of glycans greatly increase the technical difficulty, which requires very professional research personnel and extremely sophisticated analytical instruments. In order to overcome these obstacles, more methods have been developed in recent years, which have contributed to the comprehensive analysis of glycoproteins.
Core Technologies for Glycoprotein Characterization
CD BioGlyco leverages state-of-the-art technologies to deliver unparalleled accuracy and resolution in glycoprotein structure analysis. Our core technologies include advanced MS techniques, such as electrospray ionization mass spectrometry (ESI-MS) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), for precise mass measurement and glycan profiling. We also employ high-performance liquid chromatography (HPLC) and ultra-high-performance liquid chromatography (UHPLC) for efficient glycan separation and quantification. Complementing these, our nuclear magnetic resonance (NMR) spectroscopy capabilities provide atomic-level structural details of isolated glycans and glycosylation sites.
Unveiling Glycoprotein Structures with CD BioGlyco
- N-linked Glycan Analysis: We offer detailed characterization services for glycans linked to asparagine residues, including the identification of high mannose, complex, and heterogeneous glycans.
- O-linked Glycan Analysis: We offer specialized parsing services for glycans linked to serine or threonine residues, which are essential for understanding mucins and other highly glycosylated proteins.
- Glycosylation Site Mapping: Our lab offers precise identification of specific amino acid residues linked by glycan chains, providing key insights into the biological function of glycoproteins.
- Glycan Linkage Analysis: Our company offers specific glycosidic bond linkage analysis between monosaccharide units, which is essential for understanding the three-dimensional structure and recognition properties of glycans.
- Monosaccharide Composition Analysis: We provide monosaccharide fractions within glycans for precise quantitative analysis, providing clients with essential building block information.
- Quantitative Glycan Profiling: We provide precise relative and absolute quantification of glycan species in different samples or experimental conditions to enable comparisons.
SARS-CoV-2 Glycosylation Profiling

CD BioGlyco combines multiple technology platforms to provide clients with accurate SARS-CoV-2 glycosylation analysis to accelerate the development of vaccines and other therapeutic agents. Our services include the comprehensive characterization of N-linked and O-linked glycosylation sites of SARS-CoV-2 spike proteins, as well as the quantitative analysis of glycosylation structures.
Workflow

Applications
- Our services can be used to deepen the understanding of biological processes involving glycosylation, such as cell-cell communication, host-pathogen interactions, and protein folding.
- Our services are essential for characterization, quality control, and comparability studies of glycoproteins, including monoclonal antibodies, fusion proteins, and vaccines.
- Our services can be used to identify new glycoprotein biomarkers for use in disease-related conditions, particularly in oncology, inflammatory diseases, and neurodegenerative disorders.
Advantages of Us
- We pride ourselves on unparalleled analytical depth, providing not just identification but also detailed structural elucidation of even the most complex glycan modifications.
- Our high-resolution instrumentation ensures accurate mass measurements and comprehensive fragmentation data, critical for unambiguous structural assignments.
- Our team comprises experienced glycobiology experts who interpret complex data with scientific rigor, translating raw analytical outputs into meaningful biological insights.
Publication Data
Technology: MS, MS/MS
Journal: Analytical Chemistry
Published: 2023
IF: 6.7
Results: This literature provides insights into the use of MS for structure-specific N-glycoproteomics analysis, particularly the qualitative and quantitative analysis of isomeric glycopeptide structures. By synthesizing stable isotope-labeled N-glycopeptide standards, combined with collision energy modulation, the study reveals the possible rearrangement of monosaccharide units or the breakage of mannose cores in collision chambers, resulting in the generation of “Ghost” fragment ions, which leads to misassignment of glycan structures. In addition, the study describes for the first time the rearrangement phenomenon of salivary acids under collision energy, which provides a new perspective for the accurate identification of specific glycan structures in human samples. The researchers effectively prevented false-positive structure identification in glycoproteomics analysis by setting a minimum intensity threshold for fragment ions. These findings represent a critical step toward improving the accuracy and reliability of glycoproteomics measurements.
Fig.1 MS/MS spectra of G2FS IgG glycopeptides at different collision energies. (Campos, et al., 2023)
Frequently Asked Questions
CD BioGlyco provides comprehensive glycoprotein structure analysis services to help with customers' in-depth study of the heterogeneity and function of glycoproteins. Our professional research teams are proud to provide customers with different types of analysis data according to their specific needs. If you are interested in our services, please contact us to obtain more information.
Associated Services
Beyond our core glycoprotein structure analysis, CD BioGlyco offers a range of complementary services to support your comprehensive glycobiology research and development needs. These services are designed to provide a holistic understanding of your samples and facilitate your project's success.
Reference
- Campos, D.; et al. "Ghost" fragment ions in structure and site-specific glycoproteomics analysis. Analytical Chemistry. 2023, 95(27): 10145-10148. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform







